Analysis of m 6 A modulator-mediated methylation modification patterns and the tumor microenvironment in lung adenocarcinoma

Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer. In the development and progression of LUAD, epigenetic aberration plays a crucial role. However, the function of RNA N6-methyladenosine (m A) modifications in the LUAD progression is unknown. The m6A regulator modific...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 12; no. 1; p. 20684
Main Authors Zeng, Qing-Cui, Sun, Qin, Su, Wen-Jie, Li, Jia-Cen, Liu, Yi-Sha, Zhang, Kun, Yang, Li-Qing
Format Journal Article
LanguageEnglish
Published England 30.11.2022
Subjects
Adenocarcinoma of Lung - genetics
Humans
Lung Neoplasms - genetics
Methylation
Protein Processing, Post-Translational
Tumor Microenvironment - genetics
Online AccessGet full text

Cover

More Information
Summary:Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer. In the development and progression of LUAD, epigenetic aberration plays a crucial role. However, the function of RNA N6-methyladenosine (m A) modifications in the LUAD progression is unknown. The m6A regulator modification patterns in 955 LUAD samples were analyzed comprehensively. Patterns were systematically correlated with the tumor microenvironment (TME) cell-infiltration characteristics. Using principal component analysis algorithms, the m6Ascore was generated to quantify m A modification patterns in individual tumors. Then, their values for predicting prognoses and therapeutic response in LUAD patients were assessed. Three distinct m A modification patterns in LUAD were identified. Among them, the prognosis of m6Acluster C was the best, while the prognosis of m Acluster A was the worst. Interestingly, the characterization of TME cell infiltration and biological behavior differed among the three patterns. To evaluate m A modification patterns within individual tumors, an m Ascore signature was constructed. The results showed that the high m Ascore group was associated with a better prognosis; tumor somatic mutations and tumor microenvironment differed significantly between the high- and low- m Ascore groups. Furthermore, in the cohort with anti-CTLA-4 treatment alone, patients with a high m Ascore had higher ICI scores, which indicated significant therapeutic advantage and clinical benefits.
ISSN:2045-2322